BRIEF—Gritgen launches manufacturing site for hemophilia A drug

Chinese gene therapy company Gritgen Therapeutics has announced the launch of operations at its commercial GMP facility in Suzhou Industrial Park.

This milestone sets the stage for the production of Gritgen's Phase III clinical and commercial product for hemophilia A.

Gritgen has stressed that the site strictly adheres to global cGMP standards, and complies with the guidelines of regulators in China, the USA and Europe.

The facility is now a leading commercial facility for AAV-based products in China.